Joint Position Statement on the Use of Patented Microcurrent Technology for Dry AMD

The Canadian Ophthalmological Society (COS) and Canadian Retina Society (CRS) advise caution when considering a new microcurrent treatment for dry age-related macular degeneration (AMD). While early studies suggest it may help, there isn’t enough long-term evidence to confirm its safety or effectiveness. Retinal specialists, given their extensive expertise in managing age-related macular degeneration, recommend that patients and doctors discuss the treatment carefully and understand its limitations before deciding. The joint position statement is available to read below: